Compass Therapeutics (CMPX) Change in Account Payables (2019 - 2026)

Compass Therapeutics has disclosed Change in Account Payables across 8 years of filings, most recently posting -$679000.0 for Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$679000.0, down 1.04% year-over-year; the trailing twelve-month figure through Mar 2026 was -$671000.0 (down 192.81% YoY), and the FY2025 annual result was -$664000.0, up 63.93% from the prior year.
• Change in Account Payables came in at -$679000.0 for Q1 2026 at Compass Therapeutics, up from -$1.5 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $6.2 million in Q2 2022 to a low of -$3.7 million in Q3 2022.
• The 5-year median for Change in Account Payables is -$232000.0 (2024), against an average of $2294.1.
• Peak annual rise in Change in Account Payables reached 62200.0% in 2022, while the deepest fall reached 1295.47% in 2022.
• Compass Therapeutics' Change in Account Payables stood at $621000.0 in 2022, then jumped by 187.28% to $1.8 million in 2023, then slipped by 27.75% to $1.3 million in 2024, then plunged by 217.15% to -$1.5 million in 2025, then surged by 55.03% to -$679000.0 in 2026.
• The last three Change in Account Payables figures came in at -$679000.0 (Q1 2026), -$1.5 million (Q4 2025), and $500000.0 (Q3 2025), per Business Quant data.